Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, Della Porta MG; Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (https://www.fisimematologia.it/). Lanino L, et al. Among authors: galimberti s. Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24. Am J Hematol. 2023. PMID: 37222267 Free article. No abstract available.
Editorial: Measurable residual disease in hematologic malignancies.
Buccisano F, Palmieri R, Guzman ML, Galimberti S. Buccisano F, et al. Among authors: galimberti s. Front Oncol. 2023 May 10;13:1204393. doi: 10.3389/fonc.2023.1204393. eCollection 2023. Front Oncol. 2023. PMID: 37234991 Free PMC article. No abstract available.
Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients.
Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Lippolis P, Susini MC, Mazzantini E, Giubbolini R, Mavilia F, Capochiani E, Neri E, Arena C, Cerri F, De Simone L, Valentini K, Stella SM, Ricchiuto V, Bruno B, Galimberti S. Benedetti E, et al. Among authors: galimberti s. Front Oncol. 2023 Nov 1;13:1272072. doi: 10.3389/fonc.2023.1272072. eCollection 2023. Front Oncol. 2023. PMID: 38023169 Free PMC article.
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.
Mosna F, Borlenghi E, Litzow M, Byrd JC, Papayannidis C, Tecchio C, Ferrara F, Marcucci G, Cairoli R, Morgan EA, Gurrieri C, Yeung CCS, Deeg HJ, Capelli D, Candoni A, Gotlib JR, Lunghi M, Pullarkat S, Lanza F, Galimberti S, Forghieri F, Venditti A, Festuccia M, Audisio E, Marvalle D, Rigolin GM, Roti G, DiBona E, Visani G, Albano F, Eisfeld AK, Valent P, Huls G, Borthakur G, Krampera M, Martinelli G, Kröger N, Sperotto A, Gottardi M. Mosna F, et al. Among authors: galimberti s. Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.285448. Online ahead of print. Haematologica. 2024. PMID: 39385741 Free article.
Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahmé R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier AL, Dargenio M, Bonmati C, Billio A, Lejeune C, Scappini B, Pigneux A, Zappasodi P, Récher C, Grimaldi F, Adès L, Lemoli RM. Cluzeau T, et al. Among authors: galimberti s. Blood Adv. 2024 Oct 25:bloodadvances.2024014279. doi: 10.1182/bloodadvances.2024014279. Online ahead of print. Blood Adv. 2024. PMID: 39454204
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Antonioli E, Pilerci S, Attucci I, Buda G, Gozzetti A, Candi V, Simonetti F, Giudice MLD, Ciofini S, Staderini M, Grammatico S, Buzzichelli A, Messeri M, Bocchia M, Galimberti S, Vannucchi AM. Antonioli E, et al. Among authors: galimberti s. Front Oncol. 2023 Apr 25;13:1162990. doi: 10.3389/fonc.2023.1162990. eCollection 2023. Front Oncol. 2023. PMID: 37182182 Free PMC article.
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Perrone T, Re F, Galimberti S, Gini G, Capponi M, Vitolo U, Usai SV, Stefani PM, Ballerini F, Liberati AM, Pennese E, Pastore D, Skrypets T, Catellani H, Marcheselli L, Federico M, Luminari S. Nizzoli ME, et al. Among authors: galimberti s. Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28. Hematol Oncol. 2023. PMID: 37246287 Clinical Trial.
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells.
Pacelli P, Santoni A, Sicuranza A, Abruzzese E, Giai V, Crugnola M, Annunziata M, Galimberti S, Iurlo A, Luciano L, Sorà F, Fava C, Bestoso E, Marzano C, Cartocci A, Defina M, Sammartano V, Cencini E, Raspadori D, Bocchia M. Pacelli P, et al. Among authors: galimberti s. Front Pharmacol. 2023 May 26;14:1194712. doi: 10.3389/fphar.2023.1194712. eCollection 2023. Front Pharmacol. 2023. PMID: 37305536 Free PMC article.
Prospective study on the impact of BEAM versus FEAM conditioning on occurrence of neutropenic enterocolitis and on transplant outcome in lymphoma patients.
Benedetti E, Traverso G, Pucci G, Morganti R, Bramanti E, Cavallo F, Capochiani E, De Maria M, Ricchiuto V, Stella MS, Galimberti S. Benedetti E, et al. Among authors: galimberti s. Front Oncol. 2024 May 13;14:1369601. doi: 10.3389/fonc.2024.1369601. eCollection 2024. Front Oncol. 2024. PMID: 38803538 Free PMC article.
468 results